What Happens After Teva Lowered Guidance
When generics giant Teva Pharmaceuticals (NYSE:TEVA) posted flat revenue growth, the stock backed down from $10. What happens next for the stock after the lowered guidance?
In the second quarter, Teva posted an EPS of 59 cents (GAAP EPS of 19 cents). Revenue grew by 0.8% to $3.9 billion. For 2021, Teva set a net revenue range of around $16 billion. EPS for the year is $2.50 to $2.70. The strong free cash flow of $2.0 to $2.3 billion suggests that the debt reduction plans are unchanged.
Teva paid off around $500 billion in debt and now has $22.7 billion.
Teva's FCF suggests that it has the room to pay down its debt until 2023. Investors should hold the stock with at least a two-year timeframe in mind.
Investors seeking exposure to the generic drug market may consider Endo International (NASDAQ:ENDP) and Viatris (NASDAQ:VTRS). Conversely, Teva's high debts are not a concern.
On slide 19 in the earnings presentation, Teva is steadily lowering its net debt to EBITDA. Furthermore, health-care systems need Teva. For example, Teva helped nine key European markets save $9.6 billion in 2020. The health system needs generic medicines to cut costs. Teva is positioning itself to be the dominant player in this space.
TEVA stock is a good holding for the patient investor.
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.